The Global Cluster Headache Market size is expected to reach $437.5 Million by 2028, rising at a market growth of 4.0% CAGR during the forecast period.
Cluster headaches are the most prevalent among the primary trigeminal autonomic cephalgia headache forms. These headaches might happen once every two days to eight times each day, just like other trigeminal autonomic cephalgias. These happen around the same time of day, most frequently at night. Most patients experience attacks daily for weeks to months, followed by remission lasting months to years. A cluster headache is a transient unilateral headache.
Depending on how long a cluster headache lasts, it might be classified as either episodic or chronic.Chronic cluster headache attacks last more than a year without remission or less than two weeks. Cluster headaches start suddenly and without any prior pain. On one side of the head, the pain is intense and frequently characterized as searing, burning, or piercing. It is frequently felt near the eye, temple, and occasionally the cheek.
During each strike, it often targets the same side. Because of how intense the pain is during an attack; people frequently feel restless and agitated and may respond by rocking orpacing their heads. Although the precise etiology of cluster headaches is unknown, they have been associated with activity in the hypothalamus, a brain region. Smokers appear to be more susceptible to developing cluster headaches.
There may be a hereditary relationship between cluster headaches and other family members for certain people who get them. A cluster headache episode may occasionally be brought on by consuming alcohol or inhaling strong odors like paint, perfume, or gasoline. During the symptom-free phase (remission), the headaches may go away for weeks, months, or even years before returning.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Cluster headaches are the most prevalent among the primary trigeminal autonomic cephalgia headache forms. These headaches might happen once every two days to eight times each day, just like other trigeminal autonomic cephalgias. These happen around the same time of day, most frequently at night. Most patients experience attacks daily for weeks to months, followed by remission lasting months to years. A cluster headache is a transient unilateral headache.
Depending on how long a cluster headache lasts, it might be classified as either episodic or chronic.Chronic cluster headache attacks last more than a year without remission or less than two weeks. Cluster headaches start suddenly and without any prior pain. On one side of the head, the pain is intense and frequently characterized as searing, burning, or piercing. It is frequently felt near the eye, temple, and occasionally the cheek.
During each strike, it often targets the same side. Because of how intense the pain is during an attack; people frequently feel restless and agitated and may respond by rocking orpacing their heads. Although the precise etiology of cluster headaches is unknown, they have been associated with activity in the hypothalamus, a brain region. Smokers appear to be more susceptible to developing cluster headaches.
There may be a hereditary relationship between cluster headaches and other family members for certain people who get them. A cluster headache episode may occasionally be brought on by consuming alcohol or inhaling strong odors like paint, perfume, or gasoline. During the symptom-free phase (remission), the headaches may go away for weeks, months, or even years before returning.
COVID-19 Impact Analysis
Headaches from COVID-19 are a sign of systemic viral infections and a headache does not aid the diagnosis or prognosis of COVID-19 infection. Headache is a symptom of COVID-19 infection, which frequently coexists with fever and may even be reliant upon it. Also, long COVID-19 headaches may manifest as a main headache that has already started to worsen or, more precisely, as a new (intermittent or daily) headache that begins during the acute infection or after a delay. Thus, a rising occurrence of headaches in pandemic-infected individuals is projected to drive market expansion.Market Growth Factors
Increase in cluster headache frequency
the cluster headache patterns point to the hypothalamus, the body's circadian clock, as a potential contraibuting factor. Unlike migraine and tension headaches, cluster headache is typically not brought on by triggers such as certain meals, hormonal changes, or stress. Yet, consuming alcohol could swiftly create a splitting headache once a cluster phase starts. The usage of drugs like nitroglycerin, a prescription used to treat heart problems, is another potential cause. The growing prevalence of cluster headaches due to changing lifestyles and the consumption of some drugs or alcohol will propel the market growth.Improvements in medication research and available treatments
Natural compounds and their structural analogs have significantly influenced pharmacology. Recent advancements in technology and science, including enhanced analytical tools, genome mining and engineering techniques, and improvements in microbial culture, are tackling existing issues and creating new possibilities. To combat antimicrobial resistance, this has revived interest in natural compounds as drug leads.The use of natural compounds and the increasing pharmaceutical-based R&D will enhance the effectiveness of the cluster headache medications, which will drive the market expansion.
Market Restraining Factors
Limited knowledge of the conditions
Cluster headaches have no known permanent cure, and the other treatments areaimed at lessening pain intensity, minimizing the duration of the headache, and stopping episodes. Because they require quick-acting medications and their pain may arise suddenly and vanish swiftly, cluster headaches can be difficult to detect and treat. The exact etiology of cluster headaches is unknown.Cluster headaches are not subject to any tests. A doctor will often make a diagnosis by investigating a patient's symptoms and headache history and usually keepa headache journal with a list of symptoms thatmight be useful.Drug Class Outlook
Based on drug class, the cluster headache market is segmented into ergot derivatives, calcium channel blockers, triptans and others. The triptans segment dominated the cluster headache market with the maximum revenue share in 2021. This is because they are aclass, or group, of medicines that can stop migraine episodes. These drugs work to lessen symptoms by constricting enlarged blood arteries in the brain brought on by migraine attacks. Also, they are present inseveral dose formulations. Depending on thesymptoms, thedoctor may recommend a different dose type, like thedoctor could recommend a nasal spray rather than tablets to ingest if the patient isexperiencingnausea and vomiting along with themigraine.Distribution Channel Outlook
On the basis of distribution channel, the cluster headache market is divided into hospital pharmacies, drug stores & retail pharmacies and others. The drug stores & retail pharmacies segment held the highest revenue share in the cluster headache market in 2021. The growth is owing to a rise in consumer preference for retail pharmacies, which offer advice on drugs and their use throughout treatment periods.They offer first-rate customer service, affordable prices, and a large variety of general healthcare and home goods. Local pharmacists can also provide one-on-one consultations and guidance right away.Type Outlook
By type, the cluster headache market is classified into episodic and chronic. The chronic segment garnered a prominent revenue share in the cluster headache market in 2021. This is due to the fact that most people with cluster headaches suffer from the chronic kind. Chronic cluster headaches might develop from the episodic form over time, or they can be present from the start, which drives the segment's expansion. Like cluster headaches, chronic paroxysmal hemicrania (CPH) condition has shorter-lasting and more frequent symptoms, further expanding the segment growth.Regional Outlook
Region-wise, the cluster headache market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the cluster headache market in 2021. This growth isowing to an increase in cluster headache instances in the region. In addition, there isan increase in major players offering innovative therapies and the presence of improved healthcare infrastructure.With a thriving sophisticated healthcare infrastructure, andthe introduction of cutting-edge technology to detect illness, the market is anticipated to propelduring the projectedperiod.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Scope of the Study
By Distribution channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Type
- Episodic
- Chronic
By Drug Class
- Triptans
- Calcium Channel Blockers
- Ergot Derivatives
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Dr.Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Cluster Headache Market, by Distribution channel
1.4.2 Global Cluster Headache Market, by Type
1.4.3 Global Cluster Headache Market, by Drug Class
1.4.4 Global Cluster Headache Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Cluster Headache Market by Distribution channel
3.1 Global Drug Stores & Retail Pharmacies Market by Region
3.2 Global Hospital Pharmacies Market by Region
3.3 Global Others Market by Region
Chapter 4. Global Cluster Headache Market by Type
4.1 Global Episodic Market by Region
4.2 Global Chronic Market by Region
Chapter 5. Global Cluster Headache Market by Drug Class
5.1 Global Triptans Market by Region
5.2 Global Calcium Channel Blockers Market by Region
5.3 Global Ergot Derivatives Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Cluster Headache Market by Region
6.1 North America Cluster Headache Market
6.1.1 North America Cluster Headache Market by Distribution channel
6.1.1.1 North America Drug Stores & Retail Pharmacies Market by Country
6.1.1.2 North America Hospital Pharmacies Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Cluster Headache Market by Type
6.1.2.1 North America Episodic Market by Country
6.1.2.2 North America Chronic Market by Country
6.1.3 North America Cluster Headache Market by Drug Class
6.1.3.1 North America Triptans Market by Country
6.1.3.2 North America Calcium Channel Blockers Market by Country
6.1.3.3 North America Ergot Derivatives Market by Country
6.1.3.4 North America Others Market by Country
6.1.4 North America Cluster Headache Market by Country
6.1.4.1 US Cluster Headache Market
6.1.4.1.1 US Cluster Headache Market by Distribution channel
6.1.4.1.2 US Cluster Headache Market by Type
6.1.4.1.3 US Cluster Headache Market by Drug Class
6.1.4.2 Canada Cluster Headache Market
6.1.4.2.1 Canada Cluster Headache Market by Distribution channel
6.1.4.2.2 Canada Cluster Headache Market by Type
6.1.4.2.3 Canada Cluster Headache Market by Drug Class
6.1.4.3 Mexico Cluster Headache Market
6.1.4.3.1 Mexico Cluster Headache Market by Distribution channel
6.1.4.3.2 Mexico Cluster Headache Market by Type
6.1.4.3.3 Mexico Cluster Headache Market by Drug Class
6.1.4.4 Rest of North America Cluster Headache Market
6.1.4.4.1 Rest of North America Cluster Headache Market by Distribution channel
6.1.4.4.2 Rest of North America Cluster Headache Market by Type
6.1.4.4.3 Rest of North America Cluster Headache Market by Drug Class
6.2 Europe Cluster Headache Market
6.2.1 Europe Cluster Headache Market by Distribution channel
6.2.1.1 Europe Drug Stores & Retail Pharmacies Market by Country
6.2.1.2 Europe Hospital Pharmacies Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Cluster Headache Market by Type
6.2.2.1 Europe Episodic Market by Country
6.2.2.2 Europe Chronic Market by Country
6.2.3 Europe Cluster Headache Market by Drug Class
6.2.3.1 Europe Triptans Market by Country
6.2.3.2 Europe Calcium Channel Blockers Market by Country
6.2.3.3 Europe Ergot Derivatives Market by Country
6.2.3.4 Europe Others Market by Country
6.2.4 Europe Cluster Headache Market by Country
6.2.4.1 Germany Cluster Headache Market
6.2.4.1.1 Germany Cluster Headache Market by Distribution channel
6.2.4.1.2 Germany Cluster Headache Market by Type
6.2.4.1.3 Germany Cluster Headache Market by Drug Class
6.2.4.2 UK Cluster Headache Market
6.2.4.2.1 UK Cluster Headache Market by Distribution channel
6.2.4.2.2 UK Cluster Headache Market by Type
6.2.4.2.3 UK Cluster Headache Market by Drug Class
6.2.4.3 France Cluster Headache Market
6.2.4.3.1 France Cluster Headache Market by Distribution channel
6.2.4.3.2 France Cluster Headache Market by Type
6.2.4.3.3 France Cluster Headache Market by Drug Class
6.2.4.4 Russia Cluster Headache Market
6.2.4.4.1 Russia Cluster Headache Market by Distribution channel
6.2.4.4.2 Russia Cluster Headache Market by Type
6.2.4.4.3 Russia Cluster Headache Market by Drug Class
6.2.4.5 Spain Cluster Headache Market
6.2.4.5.1 Spain Cluster Headache Market by Distribution channel
6.2.4.5.2 Spain Cluster Headache Market by Type
6.2.4.5.3 Spain Cluster Headache Market by Drug Class
6.2.4.6 Italy Cluster Headache Market
6.2.4.6.1 Italy Cluster Headache Market by Distribution channel
6.2.4.6.2 Italy Cluster Headache Market by Type
6.2.4.6.3 Italy Cluster Headache Market by Drug Class
6.2.4.7 Rest of Europe Cluster Headache Market
6.2.4.7.1 Rest of Europe Cluster Headache Market by Distribution channel
6.2.4.7.2 Rest of Europe Cluster Headache Market by Type
6.2.4.7.3 Rest of Europe Cluster Headache Market by Drug Class
6.3 Asia Pacific Cluster Headache Market
6.3.1 Asia Pacific Cluster Headache Market by Distribution channel
6.3.1.1 Asia Pacific Drug Stores & Retail Pharmacies Market by Country
6.3.1.2 Asia Pacific Hospital Pharmacies Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Cluster Headache Market by Type
6.3.2.1 Asia Pacific Episodic Market by Country
6.3.2.2 Asia Pacific Chronic Market by Country
6.3.3 Asia Pacific Cluster Headache Market by Drug Class
6.3.3.1 Asia Pacific Triptans Market by Country
6.3.3.2 Asia Pacific Calcium Channel Blockers Market by Country
6.3.3.3 Asia Pacific Ergot Derivatives Market by Country
6.3.3.4 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Cluster Headache Market by Country
6.3.4.1 China Cluster Headache Market
6.3.4.1.1 China Cluster Headache Market by Distribution channel
6.3.4.1.2 China Cluster Headache Market by Type
6.3.4.1.3 China Cluster Headache Market by Drug Class
6.3.4.2 Japan Cluster Headache Market
6.3.4.2.1 Japan Cluster Headache Market by Distribution channel
6.3.4.2.2 Japan Cluster Headache Market by Type
6.3.4.2.3 Japan Cluster Headache Market by Drug Class
6.3.4.3 India Cluster Headache Market
6.3.4.3.1 India Cluster Headache Market by Distribution channel
6.3.4.3.2 India Cluster Headache Market by Type
6.3.4.3.3 India Cluster Headache Market by Drug Class
6.3.4.4 South Korea Cluster Headache Market
6.3.4.4.1 South Korea Cluster Headache Market by Distribution channel
6.3.4.4.2 South Korea Cluster Headache Market by Type
6.3.4.4.3 South Korea Cluster Headache Market by Drug Class
6.3.4.5 Singapore Cluster Headache Market
6.3.4.5.1 Singapore Cluster Headache Market by Distribution channel
6.3.4.5.2 Singapore Cluster Headache Market by Type
6.3.4.5.3 Singapore Cluster Headache Market by Drug Class
6.3.4.6 Malaysia Cluster Headache Market
6.3.4.6.1 Malaysia Cluster Headache Market by Distribution channel
6.3.4.6.2 Malaysia Cluster Headache Market by Type
6.3.4.6.3 Malaysia Cluster Headache Market by Drug Class
6.3.4.7 Rest of Asia Pacific Cluster Headache Market
6.3.4.7.1 Rest of Asia Pacific Cluster Headache Market by Distribution channel
6.3.4.7.2 Rest of Asia Pacific Cluster Headache Market by Type
6.3.4.7.3 Rest of Asia Pacific Cluster Headache Market by Drug Class
6.4 LAMEA Cluster Headache Market
6.4.1 LAMEA Cluster Headache Market by Distribution channel
6.4.1.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
6.4.1.2 LAMEA Hospital Pharmacies Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Cluster Headache Market by Type
6.4.2.1 LAMEA Episodic Market by Country
6.4.2.2 LAMEA Chronic Market by Country
6.4.3 LAMEA Cluster Headache Market by Drug Class
6.4.3.1 LAMEA Triptans Market by Country
6.4.3.2 LAMEA Calcium Channel Blockers Market by Country
6.4.3.3 LAMEA Ergot Derivatives Market by Country
6.4.3.4 LAMEA Others Market by Country
6.4.4 LAMEA Cluster Headache Market by Country
6.4.4.1 Brazil Cluster Headache Market
6.4.4.1.1 Brazil Cluster Headache Market by Distribution channel
6.4.4.1.2 Brazil Cluster Headache Market by Type
6.4.4.1.3 Brazil Cluster Headache Market by Drug Class
6.4.4.2 Argentina Cluster Headache Market
6.4.4.2.1 Argentina Cluster Headache Market by Distribution channel
6.4.4.2.2 Argentina Cluster Headache Market by Type
6.4.4.2.3 Argentina Cluster Headache Market by Drug Class
6.4.4.3 UAE Cluster Headache Market
6.4.4.3.1 UAE Cluster Headache Market by Distribution channel
6.4.4.3.2 UAE Cluster Headache Market by Type
6.4.4.3.3 UAE Cluster Headache Market by Drug Class
6.4.4.4 Saudi Arabia Cluster Headache Market
6.4.4.4.1 Saudi Arabia Cluster Headache Market by Distribution channel
6.4.4.4.2 Saudi Arabia Cluster Headache Market by Type
6.4.4.4.3 Saudi Arabia Cluster Headache Market by Drug Class
6.4.4.5 South Africa Cluster Headache Market
6.4.4.5.1 South Africa Cluster Headache Market by Distribution channel
6.4.4.5.2 South Africa Cluster Headache Market by Type
6.4.4.5.3 South Africa Cluster Headache Market by Drug Class
6.4.4.6 Nigeria Cluster Headache Market
6.4.4.6.1 Nigeria Cluster Headache Market by Distribution channel
6.4.4.6.2 Nigeria Cluster Headache Market by Type
6.4.4.6.3 Nigeria Cluster Headache Market by Drug Class
6.4.4.7 Rest of LAMEA Cluster Headache Market
6.4.4.7.1 Rest of LAMEA Cluster Headache Market by Distribution channel
6.4.4.7.2 Rest of LAMEA Cluster Headache Market by Type
6.4.4.7.3 Rest of LAMEA Cluster Headache Market by Drug Class
Chapter 7. Company Profiles
7.1 Dr. Reddy’s Laboratories Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Pfizer, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional & Segmental Analysis
7.6.4 Research & Development Expense
7.7 Fresenius SE & Co. KGaA
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Grünenthal GmbH
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.10. Arrotex Pharmaceuticals Pty Limited
7.10.1 Company Overview
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Methodology
LOADING...
